Title : Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.

Pub. Date : 2019 Oct 14

PMID : 31543464






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Asciminib, an allosteric inhibitor targeting the myristoyl-binding pocket of BCR-ABL1, is active against most single mutants but ineffective against all tested compound mutants. S-tetradecanoyl-coenzyme A BCR activator of RhoGEF and GTPase Homo sapiens